SI1901729T1 - Farmacevtske formulacije HDAC inhibitorjev - Google Patents

Farmacevtske formulacije HDAC inhibitorjev

Info

Publication number
SI1901729T1
SI1901729T1 SI200631312T SI200631312T SI1901729T1 SI 1901729 T1 SI1901729 T1 SI 1901729T1 SI 200631312 T SI200631312 T SI 200631312T SI 200631312 T SI200631312 T SI 200631312T SI 1901729 T1 SI1901729 T1 SI 1901729T1
Authority
SI
Slovenia
Prior art keywords
hdac
pharmaceutical formulations
hdac inhibitors
pertains
compositions
Prior art date
Application number
SI200631312T
Other languages
English (en)
Inventor
Richard J Bastin
Nicholas J Hughes
Original Assignee
Topotarget Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36617353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1901729(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Topotarget Uk Ltd filed Critical Topotarget Uk Ltd
Publication of SI1901729T1 publication Critical patent/SI1901729T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SI200631312T 2005-05-13 2006-05-11 Farmacevtske formulacije HDAC inhibitorjev SI1901729T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68123405P 2005-05-13 2005-05-13
US68121505P 2005-05-13 2005-05-13
PCT/GB2006/001737 WO2006120456A1 (en) 2005-05-13 2006-05-11 Pharmaceutical formulations of hdac inhibitors

Publications (1)

Publication Number Publication Date
SI1901729T1 true SI1901729T1 (sl) 2012-05-31

Family

ID=36617353

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200631312T SI1901729T1 (sl) 2005-05-13 2006-05-11 Farmacevtske formulacije HDAC inhibitorjev

Country Status (27)

Country Link
US (3) US8835501B2 (sl)
EP (2) EP2494969B1 (sl)
JP (2) JP5108750B2 (sl)
KR (2) KR101329437B1 (sl)
CN (2) CN101189003B (sl)
AT (1) ATE542527T1 (sl)
AU (1) AU2006245495B2 (sl)
BR (1) BRPI0610128B1 (sl)
CA (1) CA2606598C (sl)
CY (1) CY1112498T1 (sl)
DK (2) DK2494969T3 (sl)
EA (2) EA023400B1 (sl)
EC (1) ECSP078002A (sl)
ES (2) ES2540204T3 (sl)
HK (1) HK1110797A1 (sl)
HR (1) HRP20120341T1 (sl)
IL (2) IL187231A (sl)
MX (1) MX2007013938A (sl)
NO (1) NO339954B1 (sl)
NZ (1) NZ563236A (sl)
PL (1) PL1901729T3 (sl)
PT (1) PT1901729E (sl)
RS (1) RS52214B (sl)
SI (1) SI1901729T1 (sl)
UA (1) UA99810C2 (sl)
WO (1) WO2006120456A1 (sl)
ZA (1) ZA200710313B (sl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2500063A1 (en) 2005-02-03 2012-09-19 TopoTarget UK Limited Combination therapy using HDAC inhibitors and melphalan for treating cancer
ES2540204T3 (es) 2005-05-13 2015-07-09 Topotarget Uk Limited Formulaciones farmacéuticas de inhibidores de la HDAC
EP1957056A2 (en) 2005-11-10 2008-08-20 TopoTarget UK Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
ITRM20070038A1 (it) * 2007-01-26 2008-07-27 Uni Degli Studi Di Roma La Sapienza Forme solubili di complessi di inclusione di inibitori dell istone deacetilasi e ciclodestrine loro processi di preparazione e impieghi in campo farmaceutico
EP2192904B1 (en) * 2007-08-27 2016-08-17 Auxagen, Inc. METHODS FOR INHIBITING TGF-beta
JP2010540426A (ja) 2007-09-25 2010-12-24 トポターゲット ユーケー リミテッド 特定のヒドロキサム酸化合物の合成方法
CN102083428A (zh) * 2008-03-07 2011-06-01 顶标公司 采用长时间连续输液Belinostat进行治疗的方法
US8487006B2 (en) * 2008-09-16 2013-07-16 Auxagen, Inc. Method of enhancing TGF-β signalling
JP5773877B2 (ja) 2008-10-22 2015-09-02 アキュセラ インコーポレイテッド 眼の疾患及び障害を治療する化合物
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
WO2011064663A1 (en) 2009-11-25 2011-06-03 Festuccia, Claudio Combination treatment employing belinostat and bicalutamide
DK2688572T3 (en) 2011-03-21 2017-06-12 Valcuria Ab PHARMACEUTICAL COMPOSITION WITH AN HDAC INHIBITOR AND A STEROID AND USE THEREOF
WO2013040286A2 (en) * 2011-09-18 2013-03-21 Euro-Celtique S.A. Pharmaceutical compositions
MX2014007969A (es) * 2011-12-29 2015-02-10 Pharmacyclics Inc Hidroxiamidas de ácido cinámico como inhibidores de la histona desacetilasa 8.
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
JP6632999B2 (ja) * 2014-06-12 2020-01-22 ユニバーシティ オブ ノートルダム デュ ラック 神経疾患および大脳損傷の処置のための組成物および方法
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
WO2016149099A1 (en) 2015-03-13 2016-09-22 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as hdac8 inhibitors
EP3310350A4 (en) 2015-06-16 2019-01-09 Spectrum Pharmaceuticals, Inc. COMBINED THERAPY USING BELINOSTAT AND PRALATREXATE FOR THE TREATMENT OF LYMPHOMAS
CN105481736A (zh) * 2015-12-28 2016-04-13 山东大学 一种含有苯甘氨酸的肉桂酰胺类组蛋白去乙酰化酶抑制剂及其制备方法和应用
CA3015241A1 (en) 2016-02-22 2017-08-31 Onxeo Combination therapies comprising immuno-oncology agents and belinostat
ES2743740T3 (es) 2016-03-31 2020-02-20 Midatech Ltd Aducto de ciclodextrina-panobinostat
WO2018009531A1 (en) * 2016-07-08 2018-01-11 Ranedis Pharmaceuticals, Llc Compositions and methods of treating and/or preventing lysosomal storage diseases and other monogenetic metabolic diseases
CN107638571B (zh) * 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 一种特考韦瑞口服药物组合物及其制备方法
CN107625967B (zh) * 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 一种特考韦瑞注射用药物组合物及其制备方法
WO2018029699A1 (en) * 2016-08-11 2018-02-15 Msn Research & Development Center Solid state forms of (2e)-n-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide and process for preparation thereof
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
CN106389359B (zh) * 2016-11-30 2019-07-26 瑞阳制药有限公司 供注射用的贝利司他药物组合物及其制备方法
CN108210501B (zh) * 2016-12-14 2019-03-08 中国人民解放军军事医学科学院毒物药物研究所 一种磺酰脲类药物的注射用药物组合物及其制备方法
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
CN110996913A (zh) * 2017-06-30 2020-04-10 欧恩科斯欧公司 新的贝利司他口服制剂
US20200268788A1 (en) * 2017-08-28 2020-08-27 Asdera Llc Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
EP3687549A4 (en) * 2017-09-28 2021-07-14 Asdera LLC USE OF CYCLODEXTRIN IN DISEASES AND DISORDERS WITH PHOSPHOLIPID FAILURE REGULATION
KR20200046143A (ko) 2018-10-15 2020-05-07 주식회사 아이엠알 보안기능이 있는 Pluggable 형태의 IoT 센서 노드 및 게이트웨이 구성 방법
EP4041750A4 (en) * 2019-10-07 2023-11-01 Viracta Subsidiary, Inc. DOSAGE FOR HDAC TREATMENT WITH REDUCED SIDE EFFECTS
CN113413389B (zh) * 2021-07-19 2024-03-15 成都赜灵生物医药科技有限公司 一种组蛋白去乙酰化酶抑制剂的制剂及其制备方法和用途
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH647412A5 (de) 1980-03-25 1985-01-31 Hoffmann La Roche Pharmazeutische praeparate.
US4642316A (en) 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
DE4010536A1 (de) * 1990-04-02 1991-10-10 Boehringer Mannheim Gmbh Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure
US6071923A (en) 1994-09-16 2000-06-06 Bar-Ilan University Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
DK0861236T4 (da) 1995-11-13 2006-12-18 Sanofi Aventis Deutschland Cykliske og heterocykliske N-substituerede alphaiminohydroxam- og carboxylsyrer
WO1997030706A1 (fr) * 1996-02-26 1997-08-28 Eisai Co., Ltd. Compositions contenant un agent antitumoral
EP0827742A1 (en) 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
BR9914779A (pt) 1998-10-13 2001-07-03 Fujisawa Pharmaceutical Co Composto wf27082, processo para sua produção, composição farmacêutica contendo o mesmo, cepa de fundos pertencente ao gênero acremonium, composto tendo atividade inibidora de desacetilase de histona, processo para sua produção, seu método e uso
JP2000212088A (ja) * 1999-01-27 2000-08-02 Kobayashi Kako Kk 難溶性抗ウイルス剤の水溶液
US20070148228A1 (en) 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
CA2372053C (en) 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
AU783504C (en) 1999-11-23 2006-08-03 Methylgene Inc. Inhibitors of histone deacetylase
WO2002030879A2 (en) 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
DE60138658D1 (de) 2000-09-29 2009-06-18 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine Amidgruppe zur Behandlung von Malaria
WO2002074298A1 (fr) 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Inhibiteurs de production d'il-6
AR035455A1 (es) * 2001-04-23 2004-05-26 Hoffmann La Roche Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
ATE401395T1 (de) 2001-05-02 2008-08-15 Univ California Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
MXPA04001253A (es) 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
MXPA04001612A (es) 2001-08-21 2004-07-08 Fujisawa Pharmaceutical Co Uso medicinal de inhibidor de la histona desacetilasa y metodo para evaluar el efecto antitumoral del mismo.
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
EP1293205A1 (en) 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
CA2471932A1 (en) * 2002-01-11 2003-07-17 Matthias Rath A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
US20040091951A1 (en) 2002-02-07 2004-05-13 Axys Pharmaceuticals, Inc. Assay for measuring acetylation or deacetylation activity of an enzyme
US20050288227A1 (en) 2002-02-15 2005-12-29 Marks Paul A Use of thioredoxin measurements for diagnostics and treatments
JP2005525345A (ja) 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｔｒｘ媒介性疾患を処置する方法
EP2082737B1 (en) 2002-03-04 2014-12-31 Merck HDAC Research, LLC Methods of inducing terminal differentiation
US20070060614A1 (en) 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20040132825A1 (en) 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
OA12790A (en) 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv New inhibitors of histone deacetylase.
JP4606027B2 (ja) 2002-04-03 2011-01-05 トポターゲット ユーケー リミテッド Ｈｄａｃ阻害剤としてのピペラジン結合を有するカルバミン酸化合物
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
AU2003219595A1 (en) 2002-04-11 2003-10-27 In2Gen Co., Ltd. Alpha,Beta-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
MXPA04010199A (es) * 2002-04-15 2005-07-05 Sloan Kettering Inst Cancer Terapia en combinacion para el tratamiento de cancer.
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
JP2003321364A (ja) * 2002-05-07 2003-11-11 Eisai Co Ltd シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物
DE10233412A1 (de) 2002-07-23 2004-02-12 4Sc Ag Neue Verbindungen als Histondeacetylase-Inhibitoren
JP2005539001A (ja) 2002-08-02 2005-12-22 アージェンタ・ディスカバリー・リミテッド ヒストンデアセチラーゼインヒビターとしての置換チエニルヒドロキサム酸
US20080004311A1 (en) 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
GB0226370D0 (en) 2002-11-12 2002-12-18 Novartis Ag Organic compounds
ITMI20030025A1 (it) 2003-01-10 2004-07-11 Italfarmaco Spa Derivati dell'acido idrossammico ad attivita' antinfiammatoria.
TW200418806A (en) 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
WO2004064727A2 (en) 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
TW200424174A (en) 2003-02-06 2004-11-16 Hoffmann La Roche New TP diamide
AU2003900608A0 (en) 2003-02-11 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Hdac inhibitor
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
EP1597390A4 (en) 2003-02-18 2006-12-27 Maxcyte Inc LOADING CELLS WITH ANTIGENES BY ELECTROPORATION
WO2004082638A2 (en) 2003-03-17 2004-09-30 Syrrx, Inc. Histone deacetylase inhibitors
TW200424187A (en) 2003-04-04 2004-11-16 Hoffmann La Roche New oxime derivatives and their use as pharmaceutically active agents
SI1611088T1 (sl) 2003-04-07 2009-12-31 Pharmacyclics Inc Hidroksamati kot terapevtska sredstva
US20040220242A1 (en) 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
KR101412271B1 (ko) 2003-05-09 2014-06-25 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
AU2004241729A1 (en) 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents
EP1491188A1 (en) 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
EP1663194B1 (en) 2003-08-26 2010-03-31 Merck HDAC Research, LLC Use of SAHA for treating mesothelioma
WO2005023179A2 (en) 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
KR20050039573A (ko) * 2003-10-23 2005-04-29 주식회사 태평양 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물
CA2590257A1 (en) 2003-11-14 2005-06-09 Per Sonne Holm Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
WO2005051430A1 (de) 2003-11-14 2005-06-09 Per Sonne Holm Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
AU2003290412A1 (en) 2003-12-30 2005-07-21 Council Of Scientific And Industrial Research Arginine hydrochloride enhances chaperone-like activity of alpha crystallin
GB0401876D0 (en) 2004-01-28 2004-03-03 Vereniging Het Nl Kanker I New use for cancer antigen
CA2557568C (en) 2004-02-27 2014-05-27 Jane Trepel Pharmacodynamic assays using flow cytometry
EP1591109B1 (en) 2004-04-30 2008-07-02 TopoTarget Germany AG Formulation comprising histone deacetylase inhibitor exhibiting biphasic release
WO2005112637A1 (en) * 2004-05-14 2005-12-01 Decode Chemistry, Inc. Formulations for non-parenteral use including hydrophobic cyclodextrins
EP2476427B1 (en) 2004-08-02 2018-01-17 Zenyth Operations PTY. Ltd. A method of treating cancer comprising a VEGF-B antagonist
US20090286862A1 (en) 2004-08-06 2009-11-19 Ono Pharmaceutical Co., Ltd. Therapeutic agent for psychoneurotic disease
WO2006016680A1 (en) 2004-08-09 2006-02-16 Astellas Pharma Inc. Hydroxyamide compounds having activity as inhibitors of histone deacetylase (hdac)
WO2006060382A2 (en) 2004-11-30 2006-06-08 Trustees Of The University Of Pennsylvania Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
FR2879204B1 (fr) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
CA2610360A1 (en) 2004-12-31 2006-07-06 Per Sonne Holm E1-minus adenoviruses and use thereof
JP5475235B2 (ja) 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
EP2500063A1 (en) 2005-02-03 2012-09-19 TopoTarget UK Limited Combination therapy using HDAC inhibitors and melphalan for treating cancer
US20060229237A1 (en) 2005-04-07 2006-10-12 Yih-Lin Chung Treatment of gastrointestinal distress
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
ES2540204T3 (es) 2005-05-13 2015-07-09 Topotarget Uk Limited Formulaciones farmacéuticas de inhibidores de la HDAC
EP1743654A1 (en) 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
US20080292616A1 (en) 2005-08-19 2008-11-27 Government Of The United Of America, Represented By The Secretary, Department Of Health And.... Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same
AU2006287521A1 (en) 2005-09-07 2007-03-15 Plexxikon, Inc. PPARactive compounds
WO2007049262A1 (en) 2005-10-27 2007-05-03 Berand Limited Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders
EP1957056A2 (en) 2005-11-10 2008-08-20 TopoTarget UK Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8530493B2 (en) 2006-02-22 2013-09-10 4Sc Ag Indolopyridines as Eg5 kinesin modulators
EA015151B1 (ru) 2006-02-22 2011-06-30 4ЭсЦэ АГ Индолопиридины в качестве модуляторов кинезина eg5
GB0606096D0 (en) 2006-03-27 2006-05-03 Cbmm Sa Screening method
EP1839656A1 (en) 2006-03-31 2007-10-03 TopoTarget Germany AG Use of valproic acid for the topical treatment of mild to moderate acne vulgaris
EP2026805A1 (en) 2006-05-08 2009-02-25 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
US20070292512A1 (en) 2006-06-09 2007-12-20 Merrion Research Ii Limited Solid Oral Dosage Form Containing an Enhancer
US8338482B2 (en) 2006-07-20 2012-12-25 Wisconsin Alumni Research Foundation Modulating notch1 signaling pathway for treating neuroendocrine tumors
EP2099443A4 (en) 2006-11-10 2010-05-05 Syndax Pharmaceuticals Inc ASSOCIATION OF ERA + LIGANDS AND HISTONE DEACETYLASE INHIBITORS IN THE TREATMENT OF CANCER
US8796330B2 (en) 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
WO2008090534A1 (en) 2007-01-26 2008-07-31 Berand Limited Methods and compositions for inhibition of excessive weight gain, reduction of inappropriate eating behaviours and inhibition of binge eating for the treatment of obesity
US7915245B2 (en) 2007-02-01 2011-03-29 The Board Of Regents Of The University Of Texas System Methods and compositions of trail-death receptor agonists/activators
WO2008101121A2 (en) 2007-02-14 2008-08-21 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by muc1 and klf proteins
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
CA2726734C (en) 2007-06-06 2014-10-07 University Of Maryland, Baltimore Hdac inhibitor ms-275 and aromatase inhibitors for the treatment of cancer
US20090246198A1 (en) 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20090270497A1 (en) 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
WO2009137649A2 (en) 2008-05-07 2009-11-12 The Trustees Of The University Of Pennsylvania Methods for treating thyroid cancer

Also Published As

Publication number Publication date
NO20076366L (no) 2008-02-04
UA99810C2 (ru) 2012-10-10
AU2006245495B2 (en) 2012-09-20
DK1901729T3 (da) 2012-05-14
JP2012188444A (ja) 2012-10-04
ECSP078002A (es) 2008-01-23
CA2606598A1 (en) 2006-11-16
EA201370122A1 (ru) 2014-02-28
AU2006245495A1 (en) 2006-11-16
EA018982B1 (ru) 2013-12-30
BRPI0610128A2 (pt) 2012-09-25
DK2494969T3 (en) 2015-06-15
JP5108750B2 (ja) 2012-12-26
EP2494969B1 (en) 2015-03-25
NO339954B1 (no) 2017-02-20
RS52214B (en) 2012-10-31
ES2380887T3 (es) 2012-05-21
IL187231A0 (en) 2008-02-09
CN101189003A (zh) 2008-05-28
BRPI0610128B1 (pt) 2021-12-07
EA200702467A1 (ru) 2008-06-30
US20180072661A1 (en) 2018-03-15
IL224229A (en) 2015-09-24
KR20080016636A (ko) 2008-02-21
ES2540204T3 (es) 2015-07-09
EA023400B1 (ru) 2016-05-31
EP2494969A1 (en) 2012-09-05
KR20130079665A (ko) 2013-07-10
EP1901729A1 (en) 2008-03-26
US8835501B2 (en) 2014-09-16
PL1901729T3 (pl) 2012-07-31
HRP20120341T1 (hr) 2012-05-31
ATE542527T1 (de) 2012-02-15
JP5567068B2 (ja) 2014-08-06
NZ563236A (en) 2010-12-24
US20080194690A1 (en) 2008-08-14
CN102579417B (zh) 2014-11-26
US9856211B2 (en) 2018-01-02
MX2007013938A (es) 2008-01-28
CN102579417A (zh) 2012-07-18
HK1110797A1 (en) 2008-07-25
EP1901729B1 (en) 2012-01-25
PT1901729E (pt) 2012-04-30
IL187231A (en) 2013-11-28
KR101329437B1 (ko) 2013-11-14
CN101189003B (zh) 2012-02-08
CY1112498T1 (el) 2015-12-09
ZA200710313B (en) 2009-05-27
CA2606598C (en) 2014-12-23
US9957227B2 (en) 2018-05-01
US20150031770A1 (en) 2015-01-29
JP2008540499A (ja) 2008-11-20
WO2006120456A1 (en) 2006-11-16
KR101340824B1 (ko) 2013-12-11

Similar Documents

Publication Publication Date Title
HK1110797A1 (en) Pharmaceutical formulations of hdac inhibitors
BR0308908A (pt) Composto, composição, uso de um composto, e, métodos para inibir a hdac em uma célula, para o tratamento de uma condição mediada pela hdac, de um condição proliferativa, de câncer e de psorìase
WO2007109178A3 (en) Indole derivatives as inhibitors of histone deacetylase
WO2009129335A3 (en) Selective inhibitors of histone deacetylase
WO2005086898A3 (en) Inhibitors of histone deacetylase
NO20090783L (no) Pyrimidonforbindelser som inhibitorer av GSK-3
EP2321264A4 (en) DEACETYLASEINHIBITORS AND APPLICATIONS THEREOF
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
MY162157A (en) Substituted indole mcl-1 inhibitors
EA201500394A1 (ru) Ингибиторы деметилаз гистонов
MY144970A (en) Heterocyclic compounds
MX2014007969A (es) Hidroxiamidas de ácido cinámico como inhibidores de la histona desacetilasa 8.
BR112012032193A2 (pt) composto, composiçoes e métodos de uso de feniltioacetato
ATE439355T1 (de) 2 aminocarbonyl-substituierte piperazin- oder diaza-cyclische verbindungen als apoptose-protein-inhibitor (iap)-modulatoren
UA98757C2 (ru) Бензамидные соединения, полезные как ингибиторы деацетилазы гистонов
MX2020005841A (es) Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.
MX2021001347A (es) Inhibidores derivados de haloalilamina sulfona de lisil oxidasas y sus usos.
CY1111899T1 (el) Καινοφανη παραγωγα πυρρολης με δραστηριοτητα αναστολεα της απακετυλασης της ιστονης
TW200637824A (en) Benzamide derivatives
WO2006128120A3 (en) Novel lapachone compounds and methods of use thereof
CL2008001553A1 (es) Uso de inhibidores de desacetilasa de histona para el tratamiento de la destrucción osea causada por enfermedades proliferativas, inflamatorias o por osteoporosis.
WO2007050655A3 (en) Combination of histone deacetylase inhibitors and radiation
EA201201529A1 (ru) Комбинация ингибиторов ксантиноксидазы и статинов и ее применение